Key Competitors - Personalized Gene Therapy Treatments for Cancer Industry

The focus of targeted therapy is on the proteins, tissues, or genes that are particular to cancer and that support the survival and spread of the disease. Clinical trials are used to assess the generated medications for the market for customized gene therapy cancer treatments. Government funding and support, as well as the advantages of personalized gene therapy over conventional cancer treatment choices like chemotherapy and surgery, are the main reasons anticipated to fuel the market's expansion for these therapies. The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, for instance, was established by the American government at the MD Anderson Cancer Center in Texas to promote preclinical studies and clinical trials for targeted therapy for certain genes. Such government initiatives are motivating scientists to create more potent tailored gene therapy therapies for various cancer types, which is growing the market for such treatments. Contrarily, pharmacogenomics has an impact on physiological functions and medication reactions. The safety and effectiveness of a medicine are influenced by the differences in the processes.

According to Coherent Market Insights, in 2021, the Personalized Gene Therapy Treatments For Cancer Market was estimated to be worth USD 1.68 billion. From 2022 to 2030, it is anticipated that market size will increase at a CAGR of 19.99%.

Major Players in the Personalized Gene Therapy Treatments for Cancer Industry:

Amgen, Inc.

The company was started in 1980 and is based in California, United States. Amgen Inc. finds, develops, produces, and sells medications for severe illnesses. ChemoCentryx will be purchased by the corporation in 2022 for a total of $3.7 billion in cash. The business disclosed that it would pay $1.9 billion to buy Five Prime Therapeutics and its top candidate, bemarituzumab, in March 2021.

SynerGene Therapeutics, Inc

The company was started in 1998 and is based in Potomac, Maryland, United States. Biopharmaceutical firm SynerGene Therapeutics, Inc. The business offers molecular treatments for various cancers. The company specializes in creating nanotech cancer therapies and diagnostics based on genes.

Takara Bio, Inc., 

The company was started in 2002 and is based in Kusatsu, Shiga, Japan. Kits, reagents, tools, and other resources are made available by Takara Bio USA, Inc. to support study into the identification, regulation, and function of genes. The business introduced CDMO service for gene therapy products utilizing siTCR® technology or JAK/STAT technology in September 2022. Takara Bio unveiled "CereAAVTM," a novel brain-tropic AAV vector, for gene therapy in April 2022.

Bellicum Pharmaceuticals, Inc.

The firm was started in 2004 and is based in Houston, Texas, United States. A biopharmaceutical business called Bellicum Pharmaceuticals Inc. has found and created innovative, controlled cellular immunotherapies for a variety of cancer types, encompassing both hematologic cancers and solid tumors.

Ziopharm Oncology, Inc.

The company was founded in 1998 and is based in Houston, Texas, United States. A biopharmaceutical business called ZIOPHARM Oncology, Inc. specializes in the creation and marketing of in-licensed cancer medications. The company changed its name to Alaunos Therapeutics in January 2022 and highlighted operational progress.

OncoSec Medical, Inc.

The company was started in 2008 and is based in Ewing Township, New Jersey. An early-stage biotechnology startup called OncoSec Medical Incorporated is working to create intratumoral immunotherapies based on cytokines that will direct the body's defenses against cancer. In January 2021, OncoSec and Sirtex Medical entered into an option agreement to jointly market TAVOTM.

Burzynski Clinic

The firm was started in 1976 and is based in Houston, Texas, United States. The Burzynski Clinic offers medical amenities. The Clinic provides state-of-the-art cancer therapy, including tailored medication, traditional medicines, and follow-ups. A facility called The Burzynski Clinic offers an experimental cancer treatment.

*Definition:

In order to provide patients' cells a new function or to repair the missing or improper functioning of cells caused by cancer or gene mutations, gene therapy entails inserting genetic material into the patients' cells.